APA (7th ed.) Citation

Patel, R. P., Ghilardi, G., Porazzi, P., Yang, S., Qian, D., Pajarillo, R., . . . Ruella, M. (2022). Clinical Development of Senza5TM CART5: A Novel Dual Population CD5 CRISPR-Cas9 Knocked out Anti-CD5 Chimeric Antigen Receptor T Cell Product for Relapsed and Refractory CD5+ Nodal T-Cell Lymphomas. Blood, 140(Supplement 1), 1604-1605. https://doi.org/10.1182/blood-2022-166605

Chicago Style (17th ed.) Citation

Patel, Ruchi P., et al. "Clinical Development of Senza5TM CART5: A Novel Dual Population CD5 CRISPR-Cas9 Knocked Out Anti-CD5 Chimeric Antigen Receptor T Cell Product for Relapsed and Refractory CD5+ Nodal T-Cell Lymphomas." Blood 140, no. Supplement 1 (2022): 1604-1605. https://doi.org/10.1182/blood-2022-166605.

MLA (9th ed.) Citation

Patel, Ruchi P., et al. "Clinical Development of Senza5TM CART5: A Novel Dual Population CD5 CRISPR-Cas9 Knocked Out Anti-CD5 Chimeric Antigen Receptor T Cell Product for Relapsed and Refractory CD5+ Nodal T-Cell Lymphomas." Blood, vol. 140, no. Supplement 1, 2022, pp. 1604-1605, https://doi.org/10.1182/blood-2022-166605.